Literature DB >> 31669448

Bayesian hypothesis testing with frequentist characteristics in clinical trials.

Hui Quan1, Bingzhi Zhang2, Yu Lan2, Xiaodong Luo2, Xun Chen2.   

Abstract

Through the use of an informative prior, Bayesian methodologies could potentially borrow the strength of historical information and become more and more popular for their applications to clinical trials. Nonetheless, even with tremendous effort, the reconciliation of the formulation of the hypotheses and the calculation of type I error between a Bayesian analysis and traditional frequentist analysis is still not very clear. In this research, we apply an inferential prior, null prior and design prior to the Bayesian data analysis, type I error control and sample size calculation. As demonstrated theoretically, the type I error control denies any borrowing of favorable prior information. Thus, the use of the calibrated critical value obtained through simulation for the commensurate or power prior for a Bayesian analysis has the effect of eliminating the borrowing of historical information. The validity of a Bayesian analysis with the borrowing of historical data should rest on the a priori assumption of consistency of data from the historical and current studies. Just in case the consistency assumption is not totally true, dynamic borrowing through the commensurate or power prior can regulate the level of borrowing based on the degree of consistency in the data. An example along with simulations are used to illustrate the applications and compare the characteristics of the methods.
Copyright © 2019 Elsevier Inc. All rights reserved.

Keywords:  Design posterior; Historical data borrowing; Inferential prior; Interim analysis; Power; Type I error rate

Mesh:

Year:  2019        PMID: 31669448     DOI: 10.1016/j.cct.2019.105858

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  1 in total

1.  The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee
Journal:  Pharm Stat       Date:  2021-05-19       Impact factor: 1.234

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.